Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis

9 Feb 2024

Abstract excerpt

Neurofibromatosis Type 2 (NF2)-related schwannomatosis is a genetic disorder that causes development of multiple types of nervous system tumors. The primary and diagnostic tumor type is bilateral vestibular schwannoma. There is no cure or drug therapy for NF2. Recommended treatments include surgical resection and radiation, both of which can leave patients with severe neurological deficits or increase the risk of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Axon Guidance and Neuronal Signaling
Share to Hippo pathway signaling and YAP/TAZ
Share to Neurofibromatosis and Schwannoma Cases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38336988
DOI: 10.1038/s41388-024-02958-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosisPMID 38336988Read ↗

Simultaneous Inhibition of PI3K and PAK in Preclinical Models of Neurofibromatosis Type 2-related SchwannomatosisSemantic proximity Read ↗

Novel patient‐derived xenograft and cell line models for therapeutic screening in NF2 ‐associated schwannomaSemantic proximity Read ↗

PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2)Semantic proximity Read ↗

Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannomaSemantic proximity Read ↗

The Neurofibromatosis Type 1 Tumor Suppressor Controls Cell Growth by Regulating Signal Transducer and Activator of Transcription-3 Activity <i>In vitro</i> and <i>In vivo</i>Semantic proximity Read ↗

p21-Activated Kinases Are Required for Transformation in a Cell-Based Model of Neurofibromatosis Type 2Semantic proximity Read ↗

Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistanceSemantic proximity Read ↗

Direct and abscopal anti-tumor responses elicited by peripheral nerve schwannoma irradiation synergize with anti-PD1 treatment in vestibular schwannoma modelsSemantic proximity Read ↗

Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis.Semantic proximity Read ↗

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannomaSemantic proximity Read ↗

Preclinical validation of anti‐nuclear factor‐kappa B therapy to inhibit human vestibular schwannoma growthSemantic proximity Read ↗

Interactions among Merlin, Arkadia, and SKOR2 mediate NF2-associated human Schwann cell proliferation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.